Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Conditioning and Stem Cell Transplant for Hematologic Cancers
NCT00085449Phase 2Withdrawn
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2006
- Primary completion
- Jan 2007
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of alemtuzumab, fludarabine, melphalan, cyclosporine and mycophenolate mofetil in leukemia, lymphoma, multiple myeloma (MM) and 1 more (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Engraftment rate up to 6 years, Risk of graft-vs-host disease up to 6 years and 1 more. Planned start May 2006; status: withdrawn.
02
Drugs
alemtuzumabfludarabinemelphalancyclosporinemycophenolate mofetil
03
Conditions
leukemialymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00085449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085449.